Silo Pharma Completes $2.5 Million Registered Direct Offering at Market Price in Compliance with Nasdaq Regulations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 01 2025
0mins
Should l Buy SILO?
Source: Newsfilter
Silo Pharma's Offering: Silo Pharma, Inc. has closed a registered direct offering of 2,857,143 shares of common stock at $0.875 per share, raising approximately $2.5 million for working capital and corporate purposes.
Warrants Issued: In a concurrent private placement, the company issued unregistered warrants to purchase an equal number of shares at an exercise price of $0.75, which are immediately exercisable and will expire in five years.
Regulatory Compliance: The common stock was offered under an effective registration statement with the SEC, while the unregistered warrants were offered in a private placement and are not registered under the Securities Act.
Company Focus: Silo Pharma is a developmental-stage biopharmaceutical company targeting underserved conditions such as PTSD and chronic pain, with research collaborations with leading universities and laboratories.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SILO
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies
- Policy Acceleration: On April 18, 2026, President Trump signed an executive order directing multiple U.S. agencies to expedite research into psychedelic therapies for mental health, indicating a national focus that could create a more favorable regulatory environment for Silo Pharma's SPC-15 program.
- Innovative Treatment Approach: SPC-15, designed as a novel 5-HT4 receptor agonist, targets prophylactic treatment for PTSD and utilizes rapid nose-to-brain delivery to enhance therapeutic effects and patient compliance, potentially revolutionizing mental health treatment outcomes.
- Significant Market Opportunity: The global mental health therapeutics market is expanding, with PTSD affecting millions annually; the growing acceptance of psychedelic-assisted therapies may unlock new treatment paradigms and commercial opportunities, positioning Silo Pharma favorably in this evolving landscape.
- Clear R&D Strategy: Silo Pharma has licensed intellectual property for SPC-15 from Columbia University and is preparing for FDA IND engagement, demonstrating a strategic focus on drug delivery and clinical development aimed at leveraging evolving regulatory frameworks to accelerate innovation.
See More
Silo Pharma Advances Psychedelic Therapies for Mental Health
- Therapy Development: Silo Pharma announced plans to advance psychedelic-based therapies, particularly SPC-15 for treating post-traumatic stress disorder (PTSD), following an executive order issued by the U.S. government on April 18, 2026, aimed at accelerating research and patient access to mental health treatments.
- SPC-15 Overview: SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist delivered via an intranasal system, allowing for rapid delivery to the central nervous system, thus providing effective prophylactic treatment for PTSD patients and showcasing its potential in the mental health sector.
- Regulatory Pathway: The program is being advanced under the 505(b)(2) regulatory pathway to streamline the development timeline, enabling the company to enter clinical trials more quickly, with plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
- Market Reaction: SILO shares closed at $0.51 on Friday, up 1.18%, and are trading at $0.52 in premarket, up 0.95%, indicating a positive market response to the company's new strategic direction.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
Silo Pharma Secures Patent for PTSD Therapy
- Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
- Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
- Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
- Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.
See More
Silo Pharma Secures European Patent for Stress Disorder Prevention
- Patent Progress: Silo Pharma has received a patent allowance from the European Patent Office for an innovative approach to preventing stress-related disorders, marking a significant milestone in the biopharmaceutical sector that is expected to enhance its intellectual property portfolio and market competitiveness.
- Therapeutic Potential: The patent focuses on preventing stress-induced fear and depressive behaviors through the 5-HT4 receptor pathway, representing a shift from symptom management to prevention, which could open new avenues in mental health treatment.
- Diversified Pipeline: Silo Pharma is advancing several programs, including SPC-15 for PTSD, SP-26 for fibromyalgia, and SPC-14 for neuroinflammation, with multiple data releases expected in 2026, showcasing the company's extensive commitment to mental health.
- Broad Market Outlook: With increasing global attention on mental health, Silo Pharma's patent allowance positions it to lead in CNS therapeutics, potentially reshaping how clinicians and patients approach the management of psychiatric disorders.
See More
Silo Pharma Secures EPO Patent Approval for 5-HT4 Therapy
- Patent Approval Milestone: Silo Pharma has received a communication from the European Patent Office (EPO) indicating its intent to grant a patent for the use of 5-HT4 receptor agonists in preventing stress-related disorders, marking a significant advancement in the company's global intellectual property position and expected to enhance its strategic positioning in major European markets.
- Innovative Treatment Approach: The patent covers methods for preventing stress-induced fear and depressive-like behaviors using selected 5-HT4 receptor agonists, representing a proactive treatment strategy that targets pathways associated with stress resilience, potentially transforming the treatment landscape for stress-related disorders and addressing urgent market needs.
- Significant Market Potential: CEO Eric Weisblum emphasized that stress-related disorders represent a massive and underserved market, and the patent's approval will facilitate the advancement of the company's pipeline in this area, thereby enhancing its competitive edge.
- Global Strategic Expansion: The company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value, further solidifying its leadership position in the global mental health and stress-related treatment sectors.
See More
SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies
- Policy Acceleration: On April 18, 2026, President Trump signed an executive order directing multiple U.S. agencies to expedite research into psychedelic therapies for mental health, indicating a national focus that could create a more favorable regulatory environment for Silo Pharma's SPC-15 program.
- Innovative Treatment Approach: SPC-15, designed as a novel 5-HT4 receptor agonist, targets prophylactic treatment for PTSD and utilizes rapid nose-to-brain delivery to enhance therapeutic effects and patient compliance, potentially revolutionizing mental health treatment outcomes.
- Significant Market Opportunity: The global mental health therapeutics market is expanding, with PTSD affecting millions annually; the growing acceptance of psychedelic-assisted therapies may unlock new treatment paradigms and commercial opportunities, positioning Silo Pharma favorably in this evolving landscape.
- Clear R&D Strategy: Silo Pharma has licensed intellectual property for SPC-15 from Columbia University and is preparing for FDA IND engagement, demonstrating a strategic focus on drug delivery and clinical development aimed at leveraging evolving regulatory frameworks to accelerate innovation.
See More
Silo Pharma Advances Psychedelic Therapies for Mental Health
- Therapy Development: Silo Pharma announced plans to advance psychedelic-based therapies, particularly SPC-15 for treating post-traumatic stress disorder (PTSD), following an executive order issued by the U.S. government on April 18, 2026, aimed at accelerating research and patient access to mental health treatments.
- SPC-15 Overview: SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist delivered via an intranasal system, allowing for rapid delivery to the central nervous system, thus providing effective prophylactic treatment for PTSD patients and showcasing its potential in the mental health sector.
- Regulatory Pathway: The program is being advanced under the 505(b)(2) regulatory pathway to streamline the development timeline, enabling the company to enter clinical trials more quickly, with plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
- Market Reaction: SILO shares closed at $0.51 on Friday, up 1.18%, and are trading at $0.52 in premarket, up 0.95%, indicating a positive market response to the company's new strategic direction.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
Silo Pharma Secures Patent for PTSD Therapy
- Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
- Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
- Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
- Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.
See More
Silo Pharma Secures European Patent for Stress Disorder Prevention
- Patent Progress: Silo Pharma has received a patent allowance from the European Patent Office for an innovative approach to preventing stress-related disorders, marking a significant milestone in the biopharmaceutical sector that is expected to enhance its intellectual property portfolio and market competitiveness.
- Therapeutic Potential: The patent focuses on preventing stress-induced fear and depressive behaviors through the 5-HT4 receptor pathway, representing a shift from symptom management to prevention, which could open new avenues in mental health treatment.
- Diversified Pipeline: Silo Pharma is advancing several programs, including SPC-15 for PTSD, SP-26 for fibromyalgia, and SPC-14 for neuroinflammation, with multiple data releases expected in 2026, showcasing the company's extensive commitment to mental health.
- Broad Market Outlook: With increasing global attention on mental health, Silo Pharma's patent allowance positions it to lead in CNS therapeutics, potentially reshaping how clinicians and patients approach the management of psychiatric disorders.
See More
Silo Pharma Secures EPO Patent Approval for 5-HT4 Therapy
- Patent Approval Milestone: Silo Pharma has received a communication from the European Patent Office (EPO) indicating its intent to grant a patent for the use of 5-HT4 receptor agonists in preventing stress-related disorders, marking a significant advancement in the company's global intellectual property position and expected to enhance its strategic positioning in major European markets.
- Innovative Treatment Approach: The patent covers methods for preventing stress-induced fear and depressive-like behaviors using selected 5-HT4 receptor agonists, representing a proactive treatment strategy that targets pathways associated with stress resilience, potentially transforming the treatment landscape for stress-related disorders and addressing urgent market needs.
- Significant Market Potential: CEO Eric Weisblum emphasized that stress-related disorders represent a massive and underserved market, and the patent's approval will facilitate the advancement of the company's pipeline in this area, thereby enhancing its competitive edge.
- Global Strategic Expansion: The company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value, further solidifying its leadership position in the global mental health and stress-related treatment sectors.
See More
